Lonza Gets Exclusive Rights to Sell Lipogen’s Phosphatidylserine

October 24, 2011

Lonza says it expects to initiative launch activity in the United States in the fourth quarter of this year.

Lonza (Basel, Switzerland) has obtained exclusive rights from Lipogen (Haifa, Israel) to sell phosphatidylserine (PS) and PS-based formulations in dietary supplements, medical food, and food and beverages, under the Lonza name.

Lonza says that Lipogen is one of the world’s leading suppliers of PS and phosphatidic acid (PA). It holds several patents for the production and usage of PS in the United States, the European Union, and China.

Lonza says it expects to initiative launch activity in the United States in the fourth quarter of this year. Thereafter, it will expand to other global regions.

“Adding PS to our portfolio of branded ingredients directly represents our commitment to provide a diverse line of nutrition products and an array of formulation-friendly technical qualities,” stated Michael DeGennaro, Lonza’s global vice president, marketing and sales nutrition, in a press release. “PS represents our focus of bringing solutions that meet the needs for cognitive support to our customers.”

“Our current primary goal is to bring high-quality and efficacious brain-support ingredients to the market,” said David Rutenburg, Lipogen’s president, in the press release. “Lonza’s heritage and commitment to those same goals are well recognized in the nutrition industry. Collaborating our efforts with Lonza will further develop the high potential for PS and the modern PS Plus by meeting the needs of improving cognitive well being worldwide.”

In the press release, the companies state: “PS, which may reduce the risk of dementia and cognitive dysfunction in the elderly as well as reduce stress and mental fatigue, joins Lonza’s portfolio of nutritional ingredients backed by scientific evidence. With age, the amount of PS naturally diminishes in our brain, creating a need for supplementation. PS is the only cognitive-health ingredient in the United States which received a qualified health claim from the FDA. Lipogen PS also obtained FDA affirmed GRAS (Generally Recognized as Safe) status.”

Related Content:

News